Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Sep
18
Today In Oncology
Oral Microbiota and Risk for Pancreatic Cancer
Chronic Toxicity Rates With De-escalated vs Standard Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Addition of Metastasis-Directed SBRT to Standard Therapy in Oligometastatic Castration-Resistant Prostate Cancer
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
Policy Review HRQoL Data in Clinical Trials for Advanced Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo